Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients.

Invasive fungal diseases are important causes of morbidity and mortality in immunocompromised patients. Patients with haematological malignancies and solid cancers, as well as those with allogeneic haematopoietic stem cell and solid organ transplants, are at high risk of developing such an infection. Many fungi can cause invasive disease, with Aspergillus spp. and Candida spp. being the prevalent fungal pathogens infecting susceptible patients. During the past few years, rare moulds (for example Zygomycetes and Fusarium spp.) have come into focus as the cause of devastating clinical disease. This review aims to analyse environmental factors and parameters related to impairment of the immune system that are thought to favour the onset of invasive mould infections. Some moulds are quite common among all categories of patients, while others appear to be limited to a given subset of patients, such as allogeneic haematopoietic stem cell or solid organ transplant recipients. In addition to an exploration of factors that predispose patients to the acquisition of an invasive mould infection, prognostic factors that help to predict the eventual outcome of these infections are identified.

[1]  H. Ulmer,et al.  Airborne fungus exposure prior to hospitalisation as risk factor for mould infections in immunocompromised patients , 2012, Mycoses.

[2]  J. Latgé,et al.  Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. , 2010, Blood.

[3]  T. Peláez,et al.  Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  Michael Boeckh,et al.  Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  E. Anaissie,et al.  Factors associated with mortality in transplant patients with invasive aspergillosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  K. Yang,et al.  The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital. , 2010, American journal of infection control.

[7]  D. Kontoyiannis,et al.  Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. , 2010, The Journal of infection.

[8]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  H. Einsele,et al.  Genetic susceptibility to infections with Aspergillus fumigatus , 2010, Critical reviews in microbiology.

[10]  Giuseppe Leone,et al.  Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study , 2010, Haematologica.

[11]  S. Koo,et al.  Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis , 2010, Journal of Clinical Microbiology.

[12]  Nina Singh,et al.  Invasive Aspergillosis in Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  T. Harrison,et al.  Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  B. Lebeau,et al.  Influence of internal and outdoor factors on filamentous fungal flora in hematology wards. , 2009, American journal of infection control.

[15]  J. Sierra,et al.  Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single‐center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes , 2009, American journal of hematology/oncology.

[16]  L. Pagano,et al.  ZYGOMYCOSIS: Current approaches to management of patients with haematological malignancies , 2009, British journal of haematology.

[17]  A. Ibatici,et al.  Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients , 2009, Bone Marrow Transplantation.

[18]  M. Nucci,et al.  Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Antinori,et al.  Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002. , 2009, American journal of clinical pathology.

[20]  D. Denning,et al.  Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure , 2009, Emerging infectious diseases.

[21]  J. Guarro,et al.  Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. , 2009, Medical mycology.

[22]  Sung-Hwan Park,et al.  Invasive fungal infections in patients with systemic lupus erythematosus: experience from affiliated hospitals of Catholic University of Korea , 2009, Lupus.

[23]  J. Briones,et al.  Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT , 2009, Bone Marrow Transplantation.

[24]  W. Rutala,et al.  Preventing healthcare-associated Aspergillus infections: review of recent CDC/HICPAC recommendations. , 2009, Medical mycology.

[25]  M. Tam,et al.  STAT6-mediated suppression of erythropoiesis in an experimental model of malarial anemia , 2009, Haematologica.

[26]  B. Spellberg,et al.  Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment , 2008, Current opinion in infectious diseases.

[27]  Philippe Lutun,et al.  Factors associated with overall and attributable mortality in invasive aspergillosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  L. Zhao,et al.  Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. , 2008, The New England journal of medicine.

[29]  K. Marr,et al.  Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  D. Kontoyiannis,et al.  Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  A. Zaas,et al.  Plasminogen Alleles Influence Susceptibility to Invasive Aspergillosis , 2008, PLoS genetics.

[32]  G. Samonis,et al.  Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy , 2008 .

[33]  G. Papanicolaou,et al.  Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  J. Dipersio,et al.  Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients. , 2007 .

[35]  L. Pagano,et al.  Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  M. Schipperus,et al.  Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. , 2007, The Netherlands journal of medicine.

[37]  P. Vanhems,et al.  Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  Russell E. Lewis,et al.  Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high‐risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation , 2007, Cancer.

[39]  E. van Wijngaerden,et al.  Invasive aspergillosis in the intensive care unit. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  Y. Kanda,et al.  Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[41]  J. Mehta,et al.  Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy , 2007, Bone Marrow Transplantation.

[42]  M. Boeckh,et al.  Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  E. Leray,et al.  Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  J. Sierra,et al.  Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[45]  C. Cordonnier,et al.  Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  D. Kim,et al.  Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation , 2005, Bone Marrow Transplantation.

[47]  J. Satagopan,et al.  TLR1 and TLR6 Polymorphisms Are Associated with Susceptibility to Invasive Aspergillosis after Allogeneic Stem Cell Transplantation , 2005, Annals of the New York Academy of Sciences.

[48]  P. Muñoz,et al.  Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[50]  Nina Singh,et al.  Aspergillus Infections in Transplant Recipients , 2005, Clinical Microbiology Reviews.

[51]  J. Briones,et al.  Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis , 2004, Bone Marrow Transplantation.

[52]  R. Storb,et al.  Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[53]  G. Byrnes,et al.  Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.

[54]  D. Kontoyiannis,et al.  Fusarium infections in critically ill patients. , 2004, Seminars in respiratory and critical care medicine.

[55]  John H Rex,et al.  Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. , 2003, Blood.

[56]  M. Boeckh,et al.  Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. , 2002, Blood.

[57]  C. Maslo,et al.  Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. , 2002, The Journal of hospital infection.

[58]  D. Niederwieser,et al.  Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. , 2000, The Journal of hospital infection.

[59]  J. Rich,et al.  Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. , 1998, Chest.

[60]  G. Robson,et al.  Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. , 1994, Microbiology.

[61]  Y. Schneider,et al.  Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. , 1994, Biochemical pharmacology.

[62]  M. J. Schiff,et al.  Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. , 1991, Thorax.

[63]  Bodey Gp Infectious complications of acute leukemia. , 1966 .

[64]  P. Aronowitz,et al.  Invasive Aspergillosis , 2013, Journal of General Internal Medicine.

[65]  J. Styczyński,et al.  Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT , 2009, Bone Marrow Transplantation.

[66]  A. Terr Sick Building Syndrome: is mould the cause? , 2009, Medical mycology.

[67]  G. Samonis,et al.  Fungal infections complicating tumor necrosis factor alpha blockade therapy. , 2008, Mayo Clinic proceedings.

[68]  M. Collado,et al.  Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. , 2007, Human immunology.

[69]  W. J. Spicer,et al.  Clinical Microbiology and Infectious Diseases , 2007 .

[70]  D. Kontoyiannis,et al.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.

[71]  L. Pagano,et al.  Design and Methods , 2022 .

[72]  Nina Singh,et al.  Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  D. Denning,et al.  Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  G. Bodey Infectious complications of acute leukemia. , 1966, Medical times.